- Products to be Marketed to Clinics and Hospitals across the United States -
- Industry-Leading Pipeline in Development -
DUBLIN, Jan. 13, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the launch of a leading portfolio of generic specialty injectable medications to be marketed to hospitals across the United States.
Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO
Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The Company will be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration (FDA), as well as more than 50 additional projects currently in development.
Many of Actavis' generic specialty injectable products were previously marketed in the U.S. by Sagent Pharmaceuticals, Inc. under a manufacturing and supply agreement originally signed by the companies in 2010. Actavis regained U.S. marketing rights to the products following the expiration of the Sagent agreement on December 31, 2014.
"Over the last several years, we have been steadily growing our generic specialty injectable business around the world, marketing products in more than 50 countries," said Brent Saunders, CEO and President of Actavis. "With the addition of this diverse portfolio of injectable products to our U.S. portfolio, we will create a leading specialty injectable business within Actavis and immediately become a strong competitor in this important, high-value space. In addition, we will continue to invest in the development of our industry-leading generic injectable pipeline as part of our strategy to drive growth through complex, high-barrier-to-entry products. With our proven, well-established supply chain, experience in hospital sales from our brand anti-infective portfolio and strong existing customer relationships, our specialty injectable business is positioned to be a strong growth driver for our Company going forward "
Actavis plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.
For more information, visit Actavis' website at www.actavis.com.
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing information as of the date of this release. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actual results may differ materially from Actavis' current expectations depending upon a number of factors, risks and uncertainties affecting Actavis' business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Actavis and its third party manufacturers' facilities, products and/or businesses; the difficulty of predicting how the FDA will interpret applicable Hatch Waxman rules related to Actavis' entitlement to marketing exclusivity and the possibility that an adverse interpretation of such rules could negatively affect Actavis' marketing exclusivity; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis plc's quarterly report on Form 10-Q for the quarter ended September 30, 2014. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/actavis-launches-us-generic-specialty-injectable-portfolio-300019702.html
SOURCE Actavis plc